Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Denosumab in Combination With Enzalutamide in Progressive Metastatic Castrate-resistant Prostate Cancer and Bone Metastases.

NCT03869762 is registered in ClinicalTrials.gov with Cancer Trials Ireland as lead sponsor.

NCT NCT03869762
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03869762 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Denosumab in Combination With Enzalutamide in Progressive Metastatic Castrate-resistant Prostate Cancer and Bone Metastases.
Lead sponsor
Cancer Trials Ireland
Phase
Phase 2
Overall status
Terminated
Start date
January 9, 2019
Completion date
January 12, 2019
Enrollment
7 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

bone metastases, castration-resistant prostate cancer, metastatic cancer